Global Neurofibromatosis Treatment Drugs Market: Drivers
Increasing focus of major players on research and development of novel therapies for treating neurofibromatosis. Moreover, clinical studies are well supported by regulatory authorities which is expected to drive the growth of the global neurofibromatosis treatment drugs market. For instance, in October 2019, SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, initiated the Phase 2b ReNeu clinical trial to evaluate the mirdametinib (formerly PD-0325901), an oral, small molecule designed to inhibit MEK1 and MEK2, in children and adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NF1-PN). In July 2019, the European Commission granted Orphan Drug Designation for SpringWorks Therapeutics’ mirdametinib (formerly PD-0325901), an oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of neurofibromatosis type 1 (NF1).
North America neurofibromatosis treatment drugs market is expected to show significant growth during the forecast period owing to presence of key players and research institutes who are involved in clinical trial programmes. For instance, on November 28, 2017, the University of Alabama at Birmingham initiated phase 2 clinical study on Binimetinib in children and adults with nf1 plexiform neurofibromas. On February 18, 2020, the University of Alabama at Birmingham initiated phase 2 clinical trial of crizotinib for children and adults with neurofibromatosis type 2 and progressive vestibular.
Neurofibromatosis Treatment Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients